NCT03337646View on ClinicalTrials.gov

Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism

PHASE4CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions

Attention Deficit Hyperactivity DisorderAutism Spectrum Disorder

Interventions

DRUG

Lisdexamfetamine Dimesylate

Medication to treat ADHD

Trial Locations (1)

K2G1W2

Center for Pediatric Excellence, Ottawa

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Shire

INDUSTRY

lead

JPM van Stralen Medicine Professional

OTHER